唑来膦酸治疗恶性肿瘤高钙血症的临床效果及对不良反应发生的影响(3)
[14]张儒，吴鹏.唑来膦酸联合瑞舒伐他汀辅助治疗老年骨质疏松性椎体压缩性骨折临床观察[J].中国骨质疏松杂志，2018，24(3)：56-58.
[15] Davison M R，Lyardet L，Preliasco M，et al.Experimental model of osteonecrosis of the jaw associated to bisphosphonates(ONJBPs) in ewes chronically treated with high doses of zoledronic acid[J].Bone，2016，89(13)：68.
[16]史光彩，崔丽，郝丽，等.骨化三醇治疗维持性血液透析患者甲状旁腺功能亢进的临床疗效[J].中国现代医学杂志，2017，27(19)：74-78.
[17] Abe T，Sato T，Kokabu S，et al.Zoledronic acid increases the circulating soluble RANKL level in mice，with a further increase in lymphocyte-derived soluble RANKL in zoledronic acid- and glucocorticoid-treated mice stimulated with bacterial lipopolysaccharide[J].Cytokine，2016，83(25)：1-7.
[18] Majithia N，Atherton P J，Lafky J M，et al.Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy：a 5-year follow-up[J].Supportive Care in Cancer，2016，24(3)：1219-1226.
[19] Nagy D I，Grün A，Lévay K，et al.Efficient syntheses of zoledronic acid as an active ingredient of a drug against osteoporosis[J].Synthetic Communications，2018，48(6)：1-9.
(收稿日期：2019-03-05) (本文編辑：何玉勤), 百拇医药(何林莉)
[15] Davison M R，Lyardet L，Preliasco M，et al.Experimental model of osteonecrosis of the jaw associated to bisphosphonates(ONJBPs) in ewes chronically treated with high doses of zoledronic acid[J].Bone，2016，89(13)：68.
[16]史光彩，崔丽，郝丽，等.骨化三醇治疗维持性血液透析患者甲状旁腺功能亢进的临床疗效[J].中国现代医学杂志，2017，27(19)：74-78.
[17] Abe T，Sato T，Kokabu S，et al.Zoledronic acid increases the circulating soluble RANKL level in mice，with a further increase in lymphocyte-derived soluble RANKL in zoledronic acid- and glucocorticoid-treated mice stimulated with bacterial lipopolysaccharide[J].Cytokine，2016，83(25)：1-7.
[18] Majithia N，Atherton P J，Lafky J M，et al.Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy：a 5-year follow-up[J].Supportive Care in Cancer，2016，24(3)：1219-1226.
[19] Nagy D I，Grün A，Lévay K，et al.Efficient syntheses of zoledronic acid as an active ingredient of a drug against osteoporosis[J].Synthetic Communications，2018，48(6)：1-9.
(收稿日期：2019-03-05) (本文編辑：何玉勤), 百拇医药(何林莉)